
## Daniel R Weinberger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8334374/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intelligence, educational attainment, and brain structure in those at familial highâ€risk for schizophrenia or bipolar disorder. Human Brain Mapping, 2022, 43, 414-430.	3.6	14
2	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	1.3	61
3	Replicating G × E: The Devil and the Details. Schizophrenia Bulletin, 2022, 48, 4-4.	4.3	3
4	Electrophysiological measures from human iPSC-derived neurons are associated with schizophrenia clinical status and predict individual cognitive performance. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	29
5	Molecular phenotypes associated with antipsychotic drugs in the human caudate nucleus. Molecular Psychiatry, 2022, 27, 2061-2067.	7.9	10
6	Genetics and Brain Transcriptomics of Completed Suicide. American Journal of Psychiatry, 2022, 179, 226-241.	7.2	17
7	Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways. Nature Neuroscience, 2022, 25, 381-389.	14.8	27
8	To Model Developmental Risk in a Dish. American Journal of Psychiatry, 2022, 179, 319-321.	7.2	2
9	Molecular landscapes of human hippocampal immature neurons across lifespan. Nature, 2022, 607, 527-533.	27.8	116
10	Older molecular brain age in severe mental illness. Molecular Psychiatry, 2021, 26, 3646-3656.	7.9	23
11	Cortical cellular diversity and development in schizophrenia. Molecular Psychiatry, 2021, 26, 203-217.	7.9	11
12	Characterizing the dynamic and functional DNA methylation landscape in the developing human cortex. Epigenetics, 2021, 16, 1-13.	2.7	19
13	Structural Magnetic Resonance Imaging All Over Again. JAMA Psychiatry, 2021, 78, 11.	11.0	33
14	Placental genomic risk scores and early neurodevelopmental outcomes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	25
15	Single molecule in situ hybridization reveals distinct localizations of schizophrenia risk-related transcripts SNX19 and AS3MT in human brain. Molecular Psychiatry, 2021, 26, 3536-3547.	7.9	5
16	Comprehensive identification of somatic nucleotide variants in human brain tissue. Genome Biology, 2021, 22, 92.	8.8	26
17	Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium. Journal of Psychiatric Research, 2021, 137, 215-224.	3.1	10
18	Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Neuropsychopharmacology, 2021, 46, 1788-1801.	5.4	12

#	Article	IF	CITATIONS
19	Air Pollution Exposure Interacts With Polygenic Risk for Depression in Potentiating Stress-Related Cortical Network Connectivity. Biological Psychiatry, 2021, 89, S97-S98.	1.3	0
20	Developmental Profile of Psychiatric Risk Associated With Voltage-Gated Cation Channel Activity. Biological Psychiatry, 2021, 90, 399-408.	1.3	10
21	Genome-wide sequencing-based identification of methylation quantitative trait loci and their role in schizophrenia risk. Nature Communications, 2021, 12, 5251.	12.8	37
22	A generative-discriminative framework that integrates imaging, genetic, and diagnosis into coupled low dimensional space. Neurolmage, 2021, 238, 118200.	4.2	2
23	Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective. Biological Psychiatry, 2021, 90, 362-372.	1.3	23
24	Childhood urbanicity interacts with polygenic risk for depression to affect stress-related medial prefrontal function. Translational Psychiatry, 2021, 11, 522.	4.8	10
25	Air pollution interacts with genetic risk to influence cortical networks implicated in depression. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	22
26	Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain. Molecular Psychiatry, 2020, 25, 791-804.	7.9	86
27	Schizophrenia risk variants influence multiple classes of transcripts of sorting nexin 19 (SNX19). Molecular Psychiatry, 2020, 25, 831-843.	7.9	36
28	iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Molecular Psychiatry, 2020, 25, 2873-2888.	7.9	54
29	A Genetics Perspective on the Role of the (Neuro)Immune System in Schizophrenia. Schizophrenia Research, 2020, 217, 105-113.	2.0	43
30	Developmental effects of maternal smoking during pregnancy on the human frontal cortex transcriptome. Molecular Psychiatry, 2020, 25, 3267-3277.	7.9	16
31	KCNH2-3.1 mediates aberrant complement activation and impaired hippocampal-medial prefrontal circuitry associated with working memory deficits. Molecular Psychiatry, 2020, 25, 206-229.	7.9	13
32	Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain. Molecular Psychiatry, 2020, 25, 37-47.	7.9	98
33	Characterizing the nuclear and cytoplasmic transcriptomes in developing and mature human cortex uncovers new insight into psychiatric disease gene regulation. Genome Research, 2020, 30, 1-11.	5.5	29
34	NURR1 and ERR1 Modulate the Expression of Genes of a <i>DRD2</i> Coexpression Network Enriched for Schizophrenia Risk. Journal of Neuroscience, 2020, 40, 932-941.	3.6	19
35	Special Article: Translational Science Update. Pharmacological Implications of Emerging Schizophrenia Genetics. Journal of Clinical Psychopharmacology, 2020, 40, 323-329.	1.4	10
36	Association of Missense Mutation in FOLH1 With Decreased NAAG Levels and Impaired Working Memory Circuitry and Cognition. American Journal of Psychiatry, 2020, 177, 1129-1139.	7.2	29

#	Article	IF	CITATIONS
37	Exploiting the Variability of CACNA1C Splicing to Identify Novel, Brain-Selective Targets for Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2020, 87, S172-S173.	1.3	0
38	Missing in Action: African Ancestry Brain Research. Neuron, 2020, 107, 407-411.	8.1	12
39	Nimodipine improves cortical efficiency during working memory in healthy subjects. Translational Psychiatry, 2020, 10, 372.	4.8	11
40	Parietal-Prefrontal Feedforward Connectivity in Association With Schizophrenia Genetic Risk and Delusions. American Journal of Psychiatry, 2020, 177, 1151-1158.	7.2	11
41	A glioneuronal tumor with CLIP2-MET fusion. Npj Genomic Medicine, 2020, 5, 24.	3.8	3
42	Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk. Nature Neuroscience, 2020, 23, 510-519.	14.8	67
43	Neural substrates of smoking and reward cue reactivity in smokers: a meta-analysis of fMRI studies. Translational Psychiatry, 2020, 10, 97.	4.8	37
44	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
45	Comment on Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind. American Journal of Psychiatry, 2020, 177, 639-640.	7.2	1
46	Variation of Human Neural Stem Cells Generating Organizer States InÂVitro before Committing to Cortical Excitatory or Inhibitory Neuronal Fates. Cell Reports, 2020, 31, 107599.	6.4	20
47	Dissecting transcriptomic signatures of neuronal differentiation and maturation using iPSCs. Nature Communications, 2020, 11, 462.	12.8	96
48	Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Translational Psychiatry, 2020, 10, 158.	4.8	42
49	The fetal origins of mental illness. American Journal of Obstetrics and Gynecology, 2019, 221, 549-562.	1.3	190
50	Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. American Journal of Human Genetics, 2019, 105, 334-350.	6.2	86
51	Divergent neuronal DNA methylation patterns across human cortical development reveal critical periods and a unique role of CpH methylation. Genome Biology, 2019, 20, 196.	8.8	67
52	Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell–derived cortical interneurons from subjects with schizophrenia. Nature Neuroscience, 2019, 22, 229-242.	14.8	84
53	Neurons with Complex Karyotypes Are Rare in Aged Human Neocortex. Cell Reports, 2019, 26, 825-835.e7.	6.4	60
54	Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer's disease. Acta Neuropathologica, 2019, 137, 557-569.	7.7	73

#	Article	IF	CITATIONS
55	O29. Deconstructing Simple and Choice Decision and Movement Time in Psychosis. Biological Psychiatry, 2019, 85, S117.	1.3	0
56	O58. Childhood Urbanization Affects Prefrontal Cortical Responses to Trait Anxiety and Interacts With Polygenic Risk for Depression. Biological Psychiatry, 2019, 85, S129.	1.3	4
57	Comparison of quantitative trait loci methods: Total expression and allelic imbalance method in brain RNA-seq. PLoS ONE, 2019, 14, e0217765.	2.5	0
58	Comprehensive assessment of multiple biases in small RNA sequencing reveals significant differences in the performance of widely used methods. BMC Genomics, 2019, 20, 513.	2.8	65
59	Novel Implications For RNA In Psychiatric Genetics. European Neuropsychopharmacology, 2019, 29, S719-S720.	0.7	0
60	Regional Heterogeneity in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across Development and Schizophrenia. Neuron, 2019, 103, 203-216.e8.	8.1	158
61	The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2019, 86, 545-556.	1.3	67
62	The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia. Neuropsychopharmacology, 2019, 44, 1562-1569.	5.4	44
63	Characterization of miRNA Isoform Expression In Schizophrenia Using Postmortem Human Brain Tissue. European Neuropsychopharmacology, 2019, 29, S720.	0.7	1
64	Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients. Biological Psychiatry, 2019, 86, 45-55.	1.3	27
65	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
66	Association of a Noncoding RNA Postmortem With Suicide by Violent Means and InÂVivo With Aggressive Phenotypes. Biological Psychiatry, 2019, 85, 417-424.	1.3	13
67	Polygenic Risk Scores in Clinical Schizophrenia Research. American Journal of Psychiatry, 2019, 176, 3-4.	7.2	10
68	Thinking About Schizophrenia in an Era of Genomic Medicine. American Journal of Psychiatry, 2019, 176, 12-20.	7.2	45
69	Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents. JAMA Psychiatry, 2019, 76, 435.	11.0	51
70	Polygenic risk score increases schizophrenia liability through cognition-relevant pathways. Brain, 2019, 142, 471-485.	7.6	69
71	Schizophrenia polygenic risk score predicts mnemonic hippocampal activity. Brain, 2018, 141, 1218-1228.	7.6	36
72	Genetic risk mechanisms of posttraumatic stress disorder in the human brain. Journal of Neuroscience Research, 2018, 96, 21-30.	2.9	24

#	Article	IF	CITATIONS
73	Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data. Schizophrenia Bulletin, 2018, 44, 101-113.	4.3	41
74	Effects of Schizophrenia Polygenic Risk Scores on Brain Activity and Performance During Working Memory Subprocesses in Healthy Young Adults. Schizophrenia Bulletin, 2018, 44, 844-853.	4.3	22
75	Small RNAs May Answer Big Questions in Mental Illness. Biological Psychiatry, 2018, 83, e1-e3.	1.3	6
76	O4.1. GENETIC VULNERABILITY TO DUSP22 PROMOTOR HYPERMETHYLATION IS INVOLVED IN THE RELATION BETWEEN IN UTERO FAMINE EXPOSURE AND SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S82-S82.	4.3	0
77	Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science, 2018, 362, .	12.6	516
78	Convergence of placenta biology and genetic risk for schizophrenia. Nature Medicine, 2018, 24, 792-801.	30.7	214
79	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
80	Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nature Genetics, 2018, 50, 912-919.	21.4	893
81	Interaction of childhood urbanicity and variation in dopamine genes alters adult prefrontal function as measured by functional magnetic resonance imaging (fMRI). PLoS ONE, 2018, 13, e0195189.	2.5	13
82	Role of gamma-amino-butyric acid in the dorsal anterior cingulate in age-associated changes in cognition. Neuropsychopharmacology, 2018, 43, 2285-2291.	5.4	31
83	264. Unique Molecular Correlates of Schizophrenia and its Genetic Risk in the Hippocampus Compared to Frontal Cortex. Biological Psychiatry, 2018, 83, S107.	1.3	1
84	263. Patterns of RNA-Editing Sites in Hippocampal Dentate Gyrus Neurons. Biological Psychiatry, 2018, 83, S106-S107.	1.3	0
85	Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nature Neuroscience, 2018, 21, 1117-1125.	14.8	300
86	Multi-Trait Analysis of GWAS and Biological Insights Into Cognition: A Response to Hill (2018). Twin Research and Human Genetics, 2018, 21, 394-397.	0.6	3
87	Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3231-3235.	2.2	6
88	Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nature Communications, 2018, 9, 2265.	12.8	38
89	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
90	A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue. Schizophrenia Bulletin, 2017, 43, sbw183.	4.3	47

#	Article	IF	CITATIONS
91	New Repeat Polymorphism in the <i>AKT1</i> Gene Predicts Striatal Dopamine D2/D3 Receptor Availability and Stimulant-Induced Dopamine Release in the Healthy Human Brain. Journal of Neuroscience, 2017, 37, 4982-4991.	3.6	15
92	qSVA framework for RNA quality correction in differential expression analysis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7130-7135.	7.1	95
93	Genetic insights into the neurodevelopmental origins of schizophrenia. Nature Reviews Neuroscience, 2017, 18, 727-740.	10.2	377
94	Future of Days Past: Neurodevelopment and Schizophrenia. Schizophrenia Bulletin, 2017, 43, 1164-1168.	4.3	89
95	The neurodevelopmental origins of schizophrenia in the penumbra of genomic medicine. World Psychiatry, 2017, 16, 225-226.	10.4	30
96	Late-Onset Alzheimer's Disease Polygenic Risk Profile Score Predicts Hippocampal Function. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 673-679.	1.5	32
97	9. Polygenic Risk Profile Scores Should Predict Cognition in Schizophrenia but, for Individuals with a Large Premorbid/current IQ Difference, They Don't. Biological Psychiatry, 2017, 81, S4-S5.	1.3	0
98	187. Differential Predictors of Stress Resilience during Working Memory across Urban and Rural Upbringing. Biological Psychiatry, 2017, 81, S77-S78.	1.3	0
99	188. Effect of Stress on Prefrontal Network Effective Connectivity during Working Memory Computation. Biological Psychiatry, 2017, 81, S78.	1.3	0
100	Neanderthal-Derived Genetic Variation Shapes Modern Human Cranium and Brain. Scientific Reports, 2017, 7, 6308.	3.3	36
101	Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. Cell Reports, 2017, 21, 2597-2613.	6.4	103
102	Molecular and cellular reorganization of neural circuits in the human lineage. Science, 2017, 358, 1027-1032.	12.6	192
103	Temporal, Diagnostic, and Tissue-Specific Regulation of NRC3 Isoform Expression in Human Brain Development and Affective Disorders. American Journal of Psychiatry, 2017, 174, 256-265.	7.2	39
104	Enhancing the Informativeness and Replicability of Imaging Genomics Studies. Biological Psychiatry, 2017, 82, 157-164.	1.3	48
105	25. Cortical Information Processing in Patients With Schizophrenia is Modulated by Tolcapone: Role of COMT val158met Genotype. Schizophrenia Bulletin, 2017, 43, S17-S17.	4.3	1
106	The Dopamine D5 Receptor Is Involved in Working Memory. Frontiers in Pharmacology, 2017, 8, 666.	3.5	15
107	Dissociating Bottom-Up and Top-Down Mechanisms in the Cortico-Limbic System during Emotion Processing. Cerebral Cortex, 2016, 26, 144-155.	2.9	105
108	Automated Quality Assessment of Structural Magnetic Resonance Brain Images Based on a Supervised Machine Learning Algorithm. Frontiers in Neuroinformatics, 2016, 10, 52.	2.5	66

#	Article	IF	CITATIONS
109	Leveraging Genomic Annotations and Pleiotropic Enrichment for Improved Replication Rates in Schizophrenia GWAS. PLoS Genetics, 2016, 12, e1005803.	3.5	34
110	Genotype-Dependent Effects of COMT Inhibition on Cognitive Function in a Highly Specific, Novel Mouse Model of Altered COMT Activity. Neuropsychopharmacology, 2016, 41, 3060-3069.	5.4	18
111	Estimating changing contexts in schizophrenia. Brain, 2016, 139, 2082-2095.	7.6	38
112	Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. JAMA Psychiatry, 2016, 73, 506.	11.0	151
113	A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus. Nature Medicine, 2016, 22, 649-656.	30.7	142
114	Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model. Journal of Neuroscience, 2016, 36, 4859-4875.	3.6	47
115	Regional Variations in Brain Gyrification Are Associated with General Cognitive Ability in Humans. Current Biology, 2016, 26, 1301-1305.	3.9	81
116	Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia. Cell Reports, 2016, 16, 2116-2128.	6.4	89
117	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
118	Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell Stem Cell, 2016, 19, 248-257.	11.1	628
119	Dynamic regulation of RNA editing in human brain development and disease. Nature Neuroscience, 2016, 19, 1093-1099.	14.8	165
120	Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Behavioural Pharmacology, 2016, 27, 415-421.	1.7	16
121	Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings. American Journal of Psychiatry, 2016, 173, 527-534.	7.2	37
122	Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. JAMA Psychiatry, 2016, 73, 497.	11.0	51
123	KCNH2-3.1 expression impairs cognition and alters neuronal function in a model of molecular pathology associated with schizophrenia. Molecular Psychiatry, 2016, 21, 1517-1526.	7.9	28
124	Impact of a <i>cis</i> -associated gene expression SNP on chromosome 20q11.22 on bipolar disorder susceptibility, hippocampal structure and cognitive performance. British Journal of Psychiatry, 2016, 208, 128-137.	2.8	11
125	Altering the course of schizophrenia: progress and perspectives. Nature Reviews Drug Discovery, 2016, 15, 485-515.	46.4	410
126	Psychiatric Risk Gene Transcription Factor 4 Regulates Intrinsic Excitability of Prefrontal Neurons via Repression of SCN10a and KCNQ1. Neuron, 2016, 90, 43-55.	8.1	88

#	Article	IF	CITATIONS
127	Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nature Neuroscience, 2016, 19, 40-47.	14.8	417
128	Invalid assumptions in clustering analyses of category fluency data: Reply to Sung, Gordon and Schretlen (2015). Cortex, 2016, 75, 255-259.	2.4	6
129	The impact of Val108/158Met polymorphism of catechol-O-methyltransferase on brain oscillations during working memory. Neuroscience Letters, 2016, 610, 86-91.	2.1	3
130	Differential Response to Risperidone in Schizophrenia Patients by <i>KCNH2</i> Genotype and Drug Metabolizer Status. American Journal of Psychiatry, 2016, 173, 53-59.	7.2	24
131	Regulation of Brain-Derived Neurotrophic Factor Exocytosis and Gamma-Aminobutyric Acidergic Interneuron Synapse by the Schizophrenia Susceptibility Gene Dysbindin-1. Biological Psychiatry, 2016, 80, 312-322.	1.3	42
132	Finding the Elusive Psychiatric "Lesion―With 21st-Century Neuroanatomy: A Note of Caution. American Journal of Psychiatry, 2016, 173, 27-33.	7.2	156
133	Strong Components of Epigenetic Memory in Cultured Human Fibroblasts Related to Site of Origin and Donor Age. PLoS Genetics, 2016, 12, e1005819.	3.5	20
134	GAD2 Alternative Transcripts in the Human Prefrontal Cortex, and in Schizophrenia and Affective Disorders. PLoS ONE, 2016, 11, e0148558.	2.5	22
135	Seeking Optimal Region-Of-Interest (ROI) Single-Value Summary Measures for fMRI Studies in Imaging Genetics. PLoS ONE, 2016, 11, e0151391.	2.5	38
136	Schizophrenia. Nature Reviews Disease Primers, 2015, 1, 15067.	30.5	724
137	A variable number of tandem repeats in the 3′â€untranslated region of the dopamine transporter modulates striatal function during working memory updating across the adult age span. European Journal of Neuroscience, 2015, 42, 1912-1918.	2.6	14
138	Going beyond the current neuroinformatics infrastructure. Frontiers in Neuroinformatics, 2015, 9, 15.	2.5	2
139	Investigation of the Prenatal Expression Patterns of 108 Schizophrenia-Associated Genetic Loci. Biological Psychiatry, 2015, 77, e43-e51.	1.3	51
140	Glutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive Phenotypes. Schizophrenia Bulletin, 2015, 41, 909-918.	4.3	65
141	Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics. Neuropsychopharmacology, 2015, 40, 1600-1608.	5.4	48
142	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
143	Effect of trait anxiety on prefrontal control mechanisms during emotional conflict. Human Brain Mapping, 2015, 36, 2207-2214.	3.6	28
144	A Common Polymorphism in <i>SCN2A</i> Predicts General Cognitive Ability through Effects on PFC Physiology. Journal of Cognitive Neuroscience, 2015, 27, 1766-1774.	2.3	6

#	Article	IF	CITATIONS
145	Whither Research Domain Criteria (RDoC)?. JAMA Psychiatry, 2015, 72, 1161.	11.0	65
146	Developmental regulation of human cortex transcription and its clinical relevance at single base resolution. Nature Neuroscience, 2015, 18, 154-161.	14.8	142
147	COMT Genetic Reduction Produces Sexually Divergent Effects on Cortical Anatomy and Working Memory in Mice and Humans. Cerebral Cortex, 2015, 25, 2529-2541.	2.9	57
148	Perceptual category judgment deficits are related to prefrontal decision making abnormalities in schizophrenia. Frontiers in Psychiatry, 2014, 4, 184.	2.6	4
149	Effects of Neuregulin 3 Genotype on Human Prefrontal Cortex Physiology. Journal of Neuroscience, 2014, 34, 1051-1056.	3.6	25
150	RDoCs redux. World Psychiatry, 2014, 13, 36-38.	10.4	37
151	Prenatal Expression Patterns of Genes Associated With Neuropsychiatric Disorders. American Journal of Psychiatry, 2014, 171, 758-767.	7.2	96
152	Altered Hippocampal-Parahippocampal Function During Stimulus Encoding. JAMA Psychiatry, 2014, 71, 236.	11.0	53
153	Expression of <i>ZNF804A</i> in Human Brain and Alterations in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. JAMA Psychiatry, 2014, 71, 1112.	11.0	102
154	Differential Effects of Common Variants in <i>SCN2A</i> on General Cognitive Ability, Brain Physiology, and messenger RNA Expression in Schizophrenia Cases and Control Individuals. JAMA Psychiatry, 2014, 71, 647.	11.0	33
155	WWC1 Genotype Modulates Age-Related Decline in Episodic Memory Function Across the Adult Life Span. Biological Psychiatry, 2014, 75, 693-700.	1.3	28
156	Dynamic cortical involvement in implicit anticipation during statistical learning. Neuroscience Letters, 2014, 558, 73-77.	2.1	5
157	Characteristics of the Cation Cotransporter NKCC1 in Human Brain: Alternate Transcripts, Expression in Development, and Potential Relationships to Brain Function and Schizophrenia. Journal of Neuroscience, 2014, 34, 4929-4940.	3.6	54
158	Identification of Candidate Single-Nucleotide Polymorphisms in NRXN1 Related to Antipsychotic Treatment Response in Patients with Schizophrenia. Neuropsychopharmacology, 2014, 39, 2170-2178.	5.4	22
159	Deriving semantic structure from category fluency: Clustering techniques and their pitfalls. Cortex, 2014, 55, 130-147.	2.4	31
160	Adolescent mental health—Opportunity and obligation. Science, 2014, 346, 547-549.	12.6	358
161	Modeling a Genetic Risk for Schizophrenia in iPSCs and Mice Reveals Neural Stem Cell Deficits Associated with Adherens Junctions and Polarity. Cell Stem Cell, 2014, 15, 79-91.	11.1	238
162	Incomplete penetrance of NRXN1 deletions in families with schizophrenia. Schizophrenia Research, 2014, 155, 1-7.	2.0	39

#	Article	IF	CITATIONS
163	Category fluency, latent semantic analysis and schizophrenia: a candidate gene approach. Cortex, 2014, 55, 182-191.	2.4	67
164	The Ultimate Intra-/Extra-Dimensional Attentional Set-Shifting Task for Mice. Biological Psychiatry, 2014, 75, 660-670.	1.3	55
165	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia Research, 2014, 157, 84-89.	2.0	50
166	Genetic risk variants of schizophrenia associated with left superior temporal gyrus volume. Cortex, 2014, 58, 23-26.	2.4	22
167	Biological Effects of COMT Haplotypes and Psychosis Risk in 22q11.2 Deletion Syndrome. Biological Psychiatry, 2014, 75, 406-413.	1.3	63
168	The global cognitive impairment in schizophrenia: Consistent over decades and around the world. Schizophrenia Research, 2013, 150, 42-50.	2.0	472
169	Effect of Tolcapone on Brain Activity During a Variable Attentional Control Task: A Double-Blind, Placebo-Controlled, Counter-Balanced Trial in Healthy Volunteers. CNS Drugs, 2013, 27, 663-673.	5.9	13
170	Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease. Schizophrenia Research, 2013, 149, 162-166.	2.0	12
171	Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior. Behavioural Brain Research, 2013, 241, 173-184.	2.2	22
172	Altered Cerebral Response During Cognitive Control: A Potential Indicator of Genetic Liability for Schizophrenia. Neuropsychopharmacology, 2013, 38, 846-853.	5.4	46
173	Schizophrenia Candidate Gene ERBB4: Covert Routes of Vulnerability to Psychosis Detected at the Population Level. Schizophrenia Bulletin, 2013, 39, 349-357.	4.3	15
174	Association of <i>GSK-3β</i> Genetic Variation With GSK-3β Expression, Prefrontal Cortical Thickness, Prefrontal Physiology, and Schizophrenia. American Journal of Psychiatry, 2013, 170, 868-876.	7.2	56
175	Converging Evidence for the Association of Functional Genetic Variation in the Serotonin Receptor 2a Gene With Prefrontal Function and Olanzapine Treatment. JAMA Psychiatry, 2013, 70, 921.	11.0	46
176	Don't oversimplify psychiatric disorders. Nature, 2013, 497, 565-565.	27.8	0
177	Variation in Psychosis Gene ZNF804A Is Associated With a Refined Schizotypy Phenotype but Not Neurocognitive Performance in a Large Young Male Population. Schizophrenia Bulletin, 2013, 39, 1252-1260.	4.3	26
178	Genome-Wide Association Study of Cognitive Decline in Schizophrenia. American Journal of Psychiatry, 2013, 170, 683-684.	7.2	42
179	Effects of the BDNF Val66Met Polymorphism on White Matter Microstructure in Healthy Adults. Neuropsychopharmacology, 2013, 38, 525-532.	5.4	52
180	Effect of Schizophrenia Risk-Associated Alleles in SREB2 (GPR85) on Functional MRI Phenotypes in Healthy Volunteers. Neuropsychopharmacology, 2013, 38, 341-349.	5.4	19

#	Article	IF	CITATIONS
181	Intra- and Inter-Frequency Brain Network Structure in Health and Schizophrenia. PLoS ONE, 2013, 8, e72351.	2.5	54
182	Graph theoretical analysis of resting magnetoencephalographic functional connectivity networks. Frontiers in Computational Neuroscience, 2013, 7, 93.	2.1	33
183	DISC1 and SLC12A2 interaction affects human hippocampal function and connectivity. Journal of Clinical Investigation, 2013, 123, 2961-2964.	8.2	30
184	Characterizing the Role of Brain Derived Neurotrophic Factor Genetic Variation in Alzheimer's Disease Neurodegeneration. PLoS ONE, 2013, 8, e76001.	2.5	48
185	Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density Behavioral Neuroscience, 2012, 126, 332-343.	1.2	9
186	Investigation of Anatomical Thalamo-Cortical Connectivity and fMRI Activation in Schizophrenia. Neuropsychopharmacology, 2012, 37, 499-507.	5.4	133
187	Genetic Variation in <i>KCNH2</i> Associated With Expression in the Brain of a Unique hERG Isoform Modulates Treatment Response in Patients With Schizophrenia. American Journal of Psychiatry, 2012, 169, 725-734.	7.2	53
188	Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain, 2012, 135, 1436-1445.	7.6	53
189	Transcript-Specific Associations of SLC12A5 (KCC2) in Human Prefrontal Cortex with Development, Schizophrenia, and Affective Disorders. Journal of Neuroscience, 2012, 32, 5216-5222.	3.6	84
190	Brain-Derived Neurotrophic Factor Val <sup>66</sup> Met Polymorphism Affects Resting Regional Cerebral Blood Flow and Functional Connectivity Differentially in Women Versus Men. Journal of Neuroscience, 2012, 32, 7074-7081.	3.6	38
191	Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20160-20165.	7.1	62
192	Using latent class growth analysis to form trajectories of premorbid adjustment in schizophrenia Journal of Abnormal Psychology, 2012, 121, 388-395.	1.9	43
193	Normal aging modulates prefrontoparietal networks underlying multiple memory processes. European Journal of Neuroscience, 2012, 36, 3559-3567.	2.6	26
194	Meta-analysis and brain imaging data support the involvement of VRK2 (rs2312147) in schizophrenia susceptibility. Schizophrenia Research, 2012, 142, 200-205.	2.0	48
195	Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology, 2012, 62, 1204-1220.	4.1	102
196	Interplay between DISC1 and GABA Signaling Regulates Neurogenesis in Mice and Risk for Schizophrenia. Cell, 2012, 148, 1051-1064.	28.9	196
197	Magnitude of Impact of Executive Functioning and IQ on Episodic Memory in Schizophrenia. Biological Psychiatry, 2012, 71, 545-551.	1.3	23
198	Common and Differential Pathophysiological Features Accompany Comparable Cognitive Impairments in Medication-Free Patients with Schizophrenia and in Healthy Aging Subjects. Biological Psychiatry, 2012, 71, 890-897.	1.3	29

#	Article	IF	CITATIONS
199	Analysis of Copy Number Variations in Brain DNA from Patients with Schizophrenia and Other Psychiatric Disorders. Biological Psychiatry, 2012, 72, 651-654.	1.3	31
200	Neurophysiological correlates of age-related changes in working memory updating. Neurolmage, 2012, 62, 2151-2160.	4.2	44
201	Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12165-12170.	7.1	127
202	DNA Methylation Signatures in Development and Aging of the Human Prefrontal Cortex. American Journal of Human Genetics, 2012, 90, 260-272.	6.2	350
203	The Interleukin 3 Gene (IL3) Contributes to Human Brain Volume Variation by Regulating Proliferation and Survival of Neural Progenitors. PLoS ONE, 2012, 7, e50375.	2.5	33
204	Orientation and Cellular Distribution of Membrane-bound Catechol-O-methyltransferase in Cortical Neurons. Journal of Biological Chemistry, 2011, 286, 34752-34760.	3.4	66
205	RELN rs7341475 and Schizophrenia Risk: Confusing, yet Somehow Intriguing. Biological Psychiatry, 2011, 69, e19.	1.3	7
206	Dysbindin and Schizophrenia: It's Dopamine and Glutamate All Over Again. Biological Psychiatry, 2011, 69, 2-4.	1.3	50
207	Interactive Effects of DAOA (G72) and Catechol-O-Methyltransferase on Neurophysiology in Prefrontal Cortex. Biological Psychiatry, 2011, 69, 1006-1008.	1.3	33
208	Genetic Neuropathology of Schizophrenia: New Approaches to an Old Question and New Uses for Postmortem Human Brains. Biological Psychiatry, 2011, 69, 140-145.	1.3	83
209	Evidence of Sex-Modulated Association of ZNF804A with Schizophrenia. Biological Psychiatry, 2011, 69, 914-917.	1.3	57
210	Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature, 2011, 478, 519-523.	27.8	644
211	Selective updating of working memory content modulates meso-cortico-striatal activity. NeuroImage, 2011, 57, 1264-1272.	4.2	92
212	A closer look at siblings of patients with schizophrenia: The association of depression history and sex with cognitive phenotypes. Schizophrenia Research, 2011, 126, 164-173.	2.0	11
213	Intra-individual variability across neuropsychological tasks in schizophrenia: A comparison of patients, their siblings, and healthy controls. Schizophrenia Research, 2011, 129, 91-93.	2.0	34
214	Intermediate phenotypes in psychiatric disorders. Current Opinion in Genetics and Development, 2011, 21, 340-348.	3.3	148
215	Subjective Socioeconomic Status Predicts Human Ventral Striatal Responses to Social Status Information. Current Biology, 2011, 21, 794-797.	3.9	88
216	Spatio-temporal transcriptome of the human brain. Nature, 2011, 478, 483-489.	27.8	1,753

#	Article	IF	CITATIONS
217	Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology, 2011, 213, 563-572.	3.1	59
218	Reproducibility of prefrontal γâ€aminobutyric acid measurements with <i>J</i> â€edited spectroscopy. NMR in Biomedicine, 2011, 24, 1089-1098.	2.8	67
219	Altered Cortical Network Dynamics. Archives of General Psychiatry, 2011, 68, 1207.	12.3	161
220	Expression of GABA Signaling Molecules KCC2, NKCC1, and GAD1 in Cortical Development and Schizophrenia. Journal of Neuroscience, 2011, 31, 11088-11095.	3.6	279
221	Genetic Association of ErbB4 and Human Cortical GABA Levels <i>In Vivo</i> . Journal of Neuroscience, 2011, 31, 11628-11632.	3.6	35
222	Cognitive Factor Structure and Invariance in People With Schizophrenia, Their Unaffected Siblings, and Controls. Schizophrenia Bulletin, 2011, 37, 1157-1167.	4.3	72
223	Neurogenetic Effects of OXTR rs2254298 in the Extended Limbic System of Healthy Caucasian Adults. Biological Psychiatry, 2011, 70, e37-e39.	1.3	19
224	Data-driven methodology illustrating mechanisms underlying word list recall: Applications to clinical research Neuropsychology, 2010, 24, 625-636.	1.3	11
225	Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging. Human Genetics, 2010, 127, 441-452.	3.8	93
226	MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Human Mutation, 2010, 31, 1223-1232.	2.5	129
227	Cracking the moody brain: The rewards of self starvation. Nature Medicine, 2010, 16, 1382-1383.	30.7	47
228	Epistatic and Functional Interactions of Catechol-O-Methyltransferase (COMT) and AKT1 on Neuregulin1-ErbB Signaling in Cell Models. PLoS ONE, 2010, 5, e10789.	2.5	20
229	Common genetic variation in Neuregulin 3 ( <i>NRG3</i> ) influences risk for schizophrenia and impacts <i>NRG3</i> expression in human brain. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15619-15624.	7.1	118
230	Progranulin (GRN)in two siblings of a Latino family and in other patients with Schizophrenia. Neurocase, 2010, 16, 273-279.	0.6	41
231	Genetic Variation in FGF20 Modulates Hippocampal Biology. Journal of Neuroscience, 2010, 30, 5992-5997.	3.6	21
232	Handedness, heritability, neurocognition and brain asymmetry in schizophrenia. Brain, 2010, 133, 3113-3122.	7.6	71
233	Efficient Physical Embedding of Topologically Complex Information Processing Networks in Brains and Computer Circuits. PLoS Computational Biology, 2010, 6, e1000748.	3.2	340
234	Genetic Modulation of GABA Levels in the Anterior Cingulate Cortex by GAD1 and COMT. Neuropsychopharmacology, 2010, 35, 1708-1717.	5.4	66

#	Article	IF	CITATIONS
235	Genetic Variation in CACNA1C Affects Brain Circuitries Related to Mental Illness. Archives of General Psychiatry, 2010, 67, 939.	12.3	289
236	Modulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition. Neuropsychopharmacology, 2010, 35, 2101-2109.	5.4	70
237	Catechol-O-Methyltransferase Valine158Methionine Genotype and Resting Regional Cerebral Blood Flow in Medication-Free Patients with Schizophrenia. Biological Psychiatry, 2010, 67, 287-290.	1.3	20
238	Relative Risk of Probabilistic Category Learning Deficits in Patients with Schizophrenia and Their Siblings. Biological Psychiatry, 2010, 67, 948-955.	1.3	36
239	No Effect of a Common Allelic Variant in the Reelin Gene on Intermediate Phenotype Measures of Brain Structure, Brain Function, and Gene Expression. Biological Psychiatry, 2010, 68, 105-107.	1.3	20
240	Cognitive differences between men and women: A comparison of patients with schizophrenia and healthy volunteers. Schizophrenia Research, 2010, 120, 234-235.	2.0	27
241	Where have all the women gone?. Schizophrenia Research, 2010, 119, 240-245.	2.0	51
242	Age-related alterations in default mode network: Impact on working memory performance. Neurobiology of Aging, 2010, 31, 839-852.	3.1	444
243	Imaging genetics—days of future past. NeuroImage, 2010, 53, 804-809.	4.2	108
244	<i>DISC1</i> splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15873-15878.	7.1	162
245	Neural Correlates of Probabilistic Category Learning in Patients with Schizophrenia. Journal of Neuroscience, 2009, 29, 1244-1254.	3.6	69
246	Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19593-19598.	7.1	129
247	Variation in dopamine genes influences responsivity of the human reward system. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 617-622.	7.1	338
248	Evidence That Altered Amygdala Activity in Schizophrenia Is Related to Clinical State and Not Genetic Risk. American Journal of Psychiatry, 2009, 166, 216-225.	7.2	113
249	Age-related Alterations in Simple Declarative Memory and the Effect of Negative Stimulus Valence. Journal of Cognitive Neuroscience, 2009, 21, 1920-1933.	2.3	84
250	Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry Research - Neuroimaging, 2009, 173, 31-38.	1.8	59
251	Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition. Human Brain Mapping, 2009, 30, 3254-3264.	3.6	97
252	A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Medicine, 2009, 15, 509-518.	30.7	232

#	Article	IF	CITATIONS
253	The Role of COMT Val158Met in Cognition. Biological Psychiatry, 2009, 65, e1-e2.	1.3	67
254	Catechol-O-Methyltransferase Valine158Methionine Polymorphism Modulates Brain Networks Underlying Working Memory Across Adulthood. Biological Psychiatry, 2009, 66, 540-548.	1.3	45
255	Preferential Amygdala Reactivity to the Negative Assessment of Neutral Faces. Biological Psychiatry, 2009, 66, 847-853.	1.3	60
256	Where words fail, music speaks: Isolated memory processes in a musical patient with schizophrenia. Schizophrenia Research, 2009, 110, 197-199.	2.0	1
257	Prefrontal cognitive systems in schizophrenia : Towards human genetic brain mechanisms. Cognitive Neuropsychiatry, 2009, 14, 277-298.	1.3	80
258	Cognitive fitness of cost-efficient brain functional networks. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11747-11752.	7.1	385
259	Introduction: Genes, cognition and neuropsychiatry. Cognitive Neuropsychiatry, 2009, 14, 261-276.	1.3	8
260	Impact of interacting functional variants in COMT on regional gray matter volume in human brain. NeuroImage, 2009, 45, 44-51.	4.2	120
261	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 2009, 132, 2958-2969.	7.6	842
262	Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Structure and Function, 2008, 213, 255-271.	2.3	50
263	Association of the Ser <sup>704</sup> Cys DISC1 polymorphism with human hippocampal formation gray matter and function during memory encoding. European Journal of Neuroscience, 2008, 28, 2129-2136.	2.6	86
264	Verbal and visual memory: Characterizing the clinical and intermediate phenotype in schizophrenia. Schizophrenia Research, 2008, 105, 78-85.	2.0	67
265	Genetic Variation in Catechol-O-Methyltransferase: Effects on Working Memory in Schizophrenic Patients, Their Siblings, and Healthy Controls. Biological Psychiatry, 2008, 63, 72-79.	1.3	118
266	Is Gray Matter Volume an Intermediate Phenotype for Schizophrenia? A Voxel-Based Morphometry Study of Patients with Schizophrenia and Their Healthy Siblings. Biological Psychiatry, 2008, 63, 465-474.	1.3	179
267	Heritability of Brain Morphology Related to Schizophrenia: A Large-Scale Automated Magnetic Resonance Imaging Segmentation Study. Biological Psychiatry, 2008, 63, 475-483.	1.3	134
268	Epistasis between Dopamine Regulating Genes Identifies a Nonlinear Response of the Human Hippocampus During Memory Tasks. Biological Psychiatry, 2008, 64, 226-234.	1.3	76
269	Set-Shifting Ability and Schizophrenia: A Marker of Clinical Illness or an Intermediate Phenotype?. Biological Psychiatry, 2008, 64, 782-788.	1.3	98
270	Impact of the Brain-Derived Neurotrophic Factor Val66Met Polymorphism on Levels of Hippocampal N-Acetyl-Aspartate Assessed by Magnetic Resonance Spectroscopic Imaging at 3 Tesla. Biological Psychiatry, 2008, 64, 856-862.	1.3	36

#	Article	IF	CITATIONS
271	BDNF Val66Met polymorphism significantly affects d′ in verbal recognition memory at short and long delays. Biological Psychology, 2008, 77, 20-24.	2.2	65
272	Neurobiology of cognitive aging: Insights from imaging genetics. Biological Psychology, 2008, 79, 9-22.	2.2	65
273	False positives in imaging genetics. Neurolmage, 2008, 40, 655-661.	4.2	107
274	Genetic Dissection of the Role of Catechol- <i>O</i> -Methyltransferase in Cognition and Stress Reactivity in Mice. Journal of Neuroscience, 2008, 28, 8709-8723.	3.6	276
275	The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6133-6138.	7.1	67
276	Functional Polymorphisms in PRODH Are Associated with Risk and Protection for Schizophrenia and Fronto-Striatal Structure and Function. PLoS Genetics, 2008, 4, e1000252.	3.5	94
277	Genome-Wide Association Identifies a Common Variant in the Reelin Gene That Increases the Risk of Schizophrenia Only in Women. PLoS Genetics, 2008, 4, e28.	3.5	302
278	Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Human Molecular Genetics, 2008, 17, 2293-2309.	2.9	139
279	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. American Journal of Psychiatry, 2008, 165, 203-213.	7.2	1,863
280	Hierarchical Organization of Human Cortical Networks in Health and Schizophrenia. Journal of Neuroscience, 2008, 28, 9239-9248.	3.6	1,138
281	Expression of a GRM3 Splice Variant is Increased in the Dorsolateral Prefrontal Cortex of Individuals Carrying a Schizophrenia Risk SNP. Neuropsychopharmacology, 2008, 33, 2626-2634.	5.4	66
282	Enuresis as a premorbid developmental marker of schizophrenia. Brain, 2008, 131, 2489-2498.	7.6	31
283	The Complement System in Schizophrenia. Drug News and Perspectives, 2008, 21, 200.	1.5	123
284	Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. Journal of Clinical Investigation, 2008, 118, 2200-8.	8.2	159
285	Epistasis between catechol- <i>O</i> -methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12536-12541.	7.1	175
286	Allelic Variation in RGS4 Impacts Functional and Structural Connectivity in the Human Brain. Journal of Neuroscience, 2007, 27, 1584-1593.	3.6	98
287	Genetic contributions to white matter architecture revealed by diffusion tensor imaging in Williams syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15117-15122.	7.1	74
288	Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls. British Journal of Psychiatry, 2007, 191, 120-125.	2.8	22

#	Article	IF	CITATIONS
289	Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects. Neuropsychopharmacology, 2007, 32, 1011-1020.	5.4	219
290	α7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Human Molecular Genetics, 2007, 16, 2921-2932.	2.9	61
291	Catechol- <i>O</i> -Methyltransferase Val158Met Modulation of Prefrontal–Parietal–Striatal Brain Systems during Arithmetic and Temporal Transformations in Working Memory. Journal of Neuroscience, 2007, 27, 13393-13401.	3.6	132
292	Molecular Cloning of a Brain-specific, Developmentally Regulated Neuregulin 1 (NRG1) Isoform and Identification of a Functional Promoter Variant Associated with Schizophrenia. Journal of Biological Chemistry, 2007, 282, 24343-24351.	3.4	131
293	Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. Journal of Clinical Investigation, 2007, 117, 672-682.	8.2	205
294	Amygdala activation in affective priming: a magnetoencephalogram study. NeuroReport, 2007, 18, 1449-1453.	1.2	33
295	A validated network of effective amygdala connectivity. NeuroImage, 2007, 36, 736-745.	4.2	360
296	Treatment of Cognitive Deficits Associated with Schizophrenia. CNS Drugs, 2007, 21, 535-557.	5.9	82
297	Evidence That the BLOC-1 Protein Dysbindin Modulates Dopamine D <sub>2</sub> Receptor Internalization and Signaling But Not D <sub>1</sub> Internalization. Journal of Neuroscience, 2007, 27, 12390-12395.	3.6	119
298	Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Human Molecular Genetics, 2007, 16, 129-141.	2.9	283
299	Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: Impact of distractors. Schizophrenia Research, 2007, 89, 339-349.	2.0	95
300	Factor analysis of neurocognitive tests in a large sample of schizophrenic probands, their siblings, and healthy controls. Schizophrenia Research, 2007, 94, 231-239.	2.0	46
301	Quantifying incoherence in speech: An automated methodology and novel application to schizophrenia. Schizophrenia Research, 2007, 93, 304-316.	2.0	240
302	COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophrenia Research, 2007, 95, 253-255.	2.0	49
303	Serotonin Transporter Genotype (5-HTTLPR): Effects of Neutral and Undefined Conditions on Amygdala Activation. Biological Psychiatry, 2007, 61, 1011-1014.	1.3	122
304	Risk for Premenstrual Dysphoric Disorder Is Associated with Genetic Variation in ESR1, the Estrogen Receptor Alpha Gene. Biological Psychiatry, 2007, 62, 925-933.	1.3	140
305	Complex relationship between BOLD signal and synchronization/desynchronization of human brain MEG oscillations. Human Brain Mapping, 2007, 28, 805-816.	3.6	60
306	Schizophrenia drug says goodbye to dopamine. Nature Medicine, 2007, 13, 1018-1019.	30.7	43

#	Article	IF	CITATIONS
307	How can drug discovery for psychiatric disorders be improved?. Nature Reviews Drug Discovery, 2007, 6, 189-201.	46.4	217
308	Differentiating allocation of resources and conflict detection within attentional control processing. European Journal of Neuroscience, 2007, 25, 594-602.	2.6	33
309	Dissociating the effects of Sternberg working memory demands in prefrontal cortex. Psychiatry Research - Neuroimaging, 2007, 154, 103-114.	1.8	69
310	Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Human Genetics, 2007, 120, 889-906.	3.8	130
311	Neuregulin-1 Regulates Cell Adhesion via an ErbB2/Phosphoinositide-3 Kinase/Akt-Dependent Pathway: Potential Implications for Schizophrenia and Cancer. PLoS ONE, 2007, 2, e1369.	2.5	58
312	Therapeutic Potential of Positive AMPA Receptor Modulators in the Treatment of Neuropsychiatric Disorders. CNS Drugs, 2006, 20, 173-185.	5.9	38
313	COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. NeuroImage, 2006, 32, 1722-1732.	4.2	126
314	Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond. Biological Psychiatry, 2006, 60, 141-151.	1.3	656
315	Imaging Genetics: Perspectives from Studies of Genetically Driven Variation in Serotonin Function and Corticolimbic Affective Processing. Biological Psychiatry, 2006, 59, 888-897.	1.3	303
316	Evaluation of a Susceptibility Gene for Schizophrenia: Genotype Based Meta-Analysis of RGS4 Polymorphisms from Thirteen Independent Samples. Biological Psychiatry, 2006, 60, 152-162.	1.3	87
317	Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models. Biological Psychiatry, 2006, 59, 1180-1188.	1.3	108
318	Prefrontal-Hippocampal Coupling During Memory Processing Is Modulated by COMT Val158Met Genotype. Biological Psychiatry, 2006, 60, 1250-1258.	1.3	153
319	Schizophrenia Genes - Famine to Feast. Biological Psychiatry, 2006, 60, 81-83.	1.3	74
320	The G72/G30 Gene Complex and Cognitive Abnormalities in Schizophrenia. Neuropsychopharmacology, 2006, 31, 2022-2032.	5.4	127
321	Neurophysiological correlates of age-related changes in working memory capacity. Neuroscience Letters, 2006, 392, 32-37.	2.1	304
322	Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Human Molecular Genetics, 2006, 15, 3024-3033.	2.9	233
323	Instability of Prefrontal Signal Processing in Schizophrenia. American Journal of Psychiatry, 2006, 163, 1960-1968.	7.2	56
324	Dysfunctional Prefrontal Regional Specialization and Compensation in Schizophrenia. American Journal of Psychiatry, 2006, 163, 1969-1977.	7.2	201

#	Article	IF	CITATIONS
325	Brain regions underlying response inhibition and interference monitoring and suppression. European Journal of Neuroscience, 2006, 23, 1658-1664.	2.6	195
326	Alternative splicing of human metabotropic glutamate receptor 3. Journal of Neurochemistry, 2006, 96, 1139-1148.	3.9	51
327	Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Reviews Neuroscience, 2006, 7, 818-827.	10.2	1,166
328	Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs. NeuroRx, 2006, 3, 106-116.	6.0	15
329	Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx, 2006, 3, 97-105.	6.0	43
330	Prefrontal Electrophysiologic "Noise―and Catechol-O-Methyltransferase Genotype in Schizophrenia. Biological Psychiatry, 2006, 60, 578-584.	1.3	66
331	New directions in psychiatric therapeutics. NeuroRx, 2006, 3, 1-2.	6.0	3
332	Regional distribution of measurement error in diffusion tensor imaging. Psychiatry Research - Neuroimaging, 2006, 147, 69-78.	1.8	68
333	Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. Psychiatry Research - Neuroimaging, 2006, 147, 221-226.	1.8	53
334	Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Research - Neuroimaging, 2006, 148, 121-132.	1.8	67
335	Neonatal Ventral Hippocampal Lesions Produce an Elevation of ΔFosB-Like Protein(s) in the Rodent Neocortex. Neuropsychopharmacology, 2006, 31, 700-711.	5.4	19
336	Neuroimaging-Genetic Paradigms: A New Approach to Investigate the Pathophysiology and Treatment of Cognitive Deficits in Schizophrenia. Harvard Review of Psychiatry, 2006, 14, 78-91.	2.1	50
337	RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Human Molecular Genetics, 2006, 15, 2804-2812.	2.9	48
338	Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Human Molecular Genetics, 2006, 15, 1245-1258.	2.9	154
339	Neural mechanisms of genetic risk for impulsivity and violence in humans. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6269-6274.	7.1	793
340	Additive Effects of Genetic Variation in Dopamine Regulating Genes on Working Memory Cortical Activity in Human Brain. Journal of Neuroscience, 2006, 26, 3918-3922.	3.6	208
341	Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5â€ <sup>2</sup> SNPs associated with the disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6747-6752.	7.1	380
342	Effect of Metabotropic Glutamate Receptor 3 Genotype on <char <br="" aid="99783077">id="ital"&gt;N</char> -Acetylaspartate Measures in the Dorsolateral Prefrontal Cortex. American Journal of Psychiatry, 2006, 163, 740.	7.2	28

#	Article	IF	CITATIONS
343	Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nature Neuroscience, 2005, 8, 594-596.	14.8	402
344	5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nature Neuroscience, 2005, 8, 828-834.	14.8	1,860
345	Functional changes in the activity of brain regions underlying emotion processing in the elderly. Psychiatry Research - Neuroimaging, 2005, 139, 9-18.	1.8	130
346	The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. Journal of Neurology, 2005, 252, 833-838.	3.6	102
347	Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus. American Journal of Psychiatry, 2005, 162, 441-449.	7.2	1,933
348	Regionally Specific Disturbance of Dorsolateral Prefrontal–Hippocampal Functional Connectivity in Schizophrenia. Archives of General Psychiatry, 2005, 62, 379.	12.3	525
349	Neuroimaging and Human Genetics. International Review of Neurobiology, 2005, 67, 325-383.	2.0	21
350	Neural Mechanisms Underlying Probabilistic Category Learning in Normal Aging. Journal of Neuroscience, 2005, 25, 11340-11348.	3.6	95
351	Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4872-4877.	7.1	146
352	Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8627-8632.	7.1	479
353	Effect of Catechol-O-Methyltransferase val158met Genotype on Attentional Control. Journal of Neuroscience, 2005, 25, 5038-5045.	3.6	274
354	A conserved mRNA expression profile of SREB2 (GPR85) in adult human, monkey, and rat forebrain. Molecular Brain Research, 2005, 138, 58-69.	2.3	34
355	Variation of Human Amygdala Response During Threatening Stimuli as a Function of 5′HTTLPR Genotype and Personality Style. Biological Psychiatry, 2005, 57, 1517-1525.	1.3	194
356	Levels of processing effects on recognition memory in patients with schizophrenia. Schizophrenia Research, 2005, 74, 101-110.	2.0	28
357	Childhood-onset schizophrenia: smooth pursuit eye-tracking dysfunction in family members. Schizophrenia Research, 2005, 73, 243-252.	2.0	33
358	Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. Schizophrenia Research, 2005, 77, 261-270.	2.0	30
359	Functional, structural, and metabolic abnormalities of the hippocampal formation in Williams syndrome. Journal of Clinical Investigation, 2005, 115, 1888-1895.	8.2	134
360	Nicotine-Induced Dopamine Release in Primates Measured with [11C]Raclopride PET. Neuropsychopharmacology, 2004, 29, 259-268.	5.4	57

#	Article	IF	CITATIONS
361	Effects of Chronic Haloperidol and Clozapine Treatment on Neurogenesis in the Adult Rat Hippocampus. Neuropsychopharmacology, 2004, 29, 1063-1069.	5.4	170
362	Variation in <i>GRM3</i> affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12604-12609.	7.1	381
363	Interaction of COMT Val <sup>108/158</sup> Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia. American Journal of Psychiatry, 2004, 161, 1798-1805.	7.2	281
364	Prefrontal Broadband Noise, Working Memory, and Genetic Risk for Schizophrenia. American Journal of Psychiatry, 2004, 161, 490-500.	7.2	218
365	The Brain-Derived Neurotrophic Factor val66met Polymorphism and Variation in Human Cortical Morphology. Journal of Neuroscience, 2004, 24, 10099-10102.	3.6	807
366	Lack of false recognition in schizophrenia: a consequence of poor memory?. Neuropsychologia, 2004, 42, 546-554.	1.6	52
367	Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study. Psychiatry Research - Neuroimaging, 2004, 131, 95-105.	1.8	52
368	Gene Expression of Metabolic Enzymes and a Protease Inhibitor in the Prefrontal Cortex Are Decreased in Schizophrenia. Neurochemical Research, 2004, 29, 1245-1255.	3.3	85
369	Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Human Molecular Genetics, 2004, 13, 2699-2708.	2.9	334
370	Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biological Psychiatry, 2004, 55, 976-980.	1.3	143
371	Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biological Psychiatry, 2004, 56, 190-197.	1.3	69
372	Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 2004, 56, 301-307.	1.3	818
373	Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological Psychiatry, 2004, 56, 677-682.	1.3	137
374	Genes and the parsing of cognitive processes. Trends in Cognitive Sciences, 2004, 8, 325-335.	7.8	336
375	Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neurosciences, 2004, 27, 683-690.	8.6	576
376	Amphetamine Modulates Human Incentive Processing. Neuron, 2004, 43, 261-269.	8.1	158
377	Functional Analysis of Genetic Variation in Catechol-O-Methyltransferase (COMT): Effects on mRNA, Protein, and Enzyme Activity in Postmortem Human Brain. American Journal of Human Genetics, 2004, 75, 807-821.	6.2	1,495
378	Cortical signal-to-noise ratio: insight into the pathophysiology and genetics of schizophrenia. Clinical Neuroscience Research, 2003, 3, 55-66.	0.8	17

#	Article	IF	CITATIONS
379	Glycogen synthase kinase (CSK)-3β levels and activity in a neurodevelopmental rat model of schizophrenia. Developmental Brain Research, 2003, 141, 33-37.	1.7	31
380	Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. European Journal of Neuroscience, 2003, 18, 391-402.	2.6	101
381	Neonatal ventral hippocampal damage modifies serum corticosterone and dopamine release responses to acute footshock in adult Sprague-Dawley rats. Synapse, 2003, 47, 270-277.	1.2	35
382	The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. European Journal of Neuroscience, 2003, 18, 3097-3104.	2.6	97
383	Single-cue delay and trace classical conditioning in schizophrenia. Biological Psychiatry, 2003, 53, 390-402.	1.3	33
384	Neocortical modulation of the amygdala response to fearful stimuli. Biological Psychiatry, 2003, 53, 494-501.	1.3	764
385	Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biological Psychiatry, 2003, 53, 906-913.	1.3	191
386	Imaging genomics. British Medical Bulletin, 2003, 65, 259-270.	6.9	305
387	The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function. Cell, 2003, 112, 257-269.	28.9	3,472
388	Functional and effective frontotemporal connectivity and genetic risk for schizophrenia. Biological Psychiatry, 2003, 54, 1181-1192.	1.3	128
389	Size of the human corpus callosum is genetically determined: an MRI study in mono and dizygotic twins. Neuroscience Letters, 2003, 338, 91-94.	2.1	67
390	The anxiogenic β-carboline FG-7142 inhibits locomotor exploration similarly in postweanling and adult rats. Neuroscience Letters, 2003, 346, 5-8.	2.1	5
391	Behavioral effects of neonatal and adult excitotoxic lesions of the mediodorsal thalamus in the adult rat. Behavioural Brain Research, 2003, 141, 105-111.	2.2	15
392	Abnormal fMRI Response of the Dorsolateral Prefrontal Cortex in Cognitively Intact Siblings of Patients With Schizophrenia. American Journal of Psychiatry, 2003, 160, 709-719.	7.2	417
393	In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia. American Journal of Psychiatry, 2003, 160, 118-127.	7.2	231
394	Catechol <i>O</i> -methyltransferase <i>val</i> <sup> <i>158</i> </sup> <i>-met</i> genotype and individual variation in the brain response to amphetamine. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6186-6191.	7.1	891
395	Central Muscarinic Acetylcholine Receptor Availability in Patients Treated with Clozapine. Neuropsychopharmacology, 2003, 28, 1531-1537.	5.4	48
396	Complexity of Prefrontal Cortical Dysfunction in Schizophrenia: More Than Up or Down. American Journal of Psychiatry, 2003, 160, 2209-2215.	7.2	644

#	Article	IF	CITATIONS
397	Catechol O-Methyltransferase (COMT) mRNA Expression in the Dorsolateral Prefrontal Cortex of Patients with Schizophrenia. Neuropsychopharmacology, 2003, 28, 1521-1530.	5.4	126
398	Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds. Neuropsychopharmacology, 2003, 28, 1491-1500.	5.4	69
399	Working Memory Deficits and Levels ofN-Acetylaspartate in Patients With Schizophreniform Disorder. American Journal of Psychiatry, 2003, 160, 483-489.	7.2	73
400	Parental Schizophrenia Spectrum Disorders in Childhood-Onset and Adult-Onset Schizophrenia. American Journal of Psychiatry, 2003, 160, 490-495.	7.2	103
401	Schizophrenia, III. American Journal of Psychiatry, 2003, 160, 1242-1242.	7.2	59
402	Catechol- <i>O</i> -Methyltransferase Genotype and Dopamine Regulation in the Human Brain. Journal of Neuroscience, 2003, 23, 2008-2013.	3.6	294
403	Brain-Derived Neurotrophic Factor val <sup>66</sup> met Polymorphism Affects Human Memory-Related Hippocampal Activity and Predicts Memory Performance. Journal of Neuroscience, 2003, 23, 6690-6694.	3.6	916
404	Genetic and physiological data implicating the new human gene G72 and the gene for <scp>d</scp> -amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13675-13680.	7.1	785
405	Habit and Skill Learning in Schizophrenia: Evidence of Normal Striatal Processing With Abnormal Cortical Input. Learning and Memory, 2002, 9, 430-442.	1.3	102
406	The Human Genome: Mutations. American Journal of Psychiatry, 2002, 159, 12-12.	7.2	15
407	Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease. Journal of Neuroscience, 2002, 22, 9099-9103.	3.6	261
408	Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophrenia Research, 2002, 57, 221-226.	2.0	63
409	Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophrenia Research, 2002, 58, 11-20.	2.0	261
410	Cortical Systems Associated with Covert Music Rehearsal. NeuroImage, 2002, 16, 901-908.	4.2	87
411	The Amygdala Response to Emotional Stimuli: A Comparison of Faces and Scenes. NeuroImage, 2002, 17, 317-323.	4.2	829
412	The phonological similarity effect in short-term memory serial recall in schizophrenia. Psychiatry Research, 2002, 112, 77-81.	3.3	9
413	Serotonin Transporter Genetic Variation and the Response of the Human Amygdala. Science, 2002, 297, 400-403.	12.6	2,227
414	Effects of Reversible Inactivation of the Neonatal Ventral Hippocampus on Behavior in the Adult Rat. Journal of Neuroscience, 2002, 22, 2835-2842.	3.6	119

#	Article	IF	CITATIONS
415	Neonatal Damage of the Ventral Hippocampus Impairs Working Memory in the Rat. Neuropsychopharmacology, 2002, 27, 47-54.	5.4	188
416	Dextroamphetamine Modulates the Response of the Human Amygdala. Neuropsychopharmacology, 2002, 27, 1036-1040.	5.4	160
417	Thalamic and caudate volumes in monozygotic twins discordant for schizophrenia. Australian and New Zealand Journal of Psychiatry, 2002, 36, 347-354.	2.3	27
418	Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience, 2002, 5, 267-271.	14.8	603
419	A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus. Neurotoxicity Research, 2002, 4, 469-475.	2.7	134
420	Biological phenotypes and genetic research on schizophrenia. World Psychiatry, 2002, 1, 2-6.	10.4	21
421	An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia. Schizophrenia Research, 2001, 49, 129-143.	2.0	109
422	Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biological Psychiatry, 2001, 49, 528-539.	1.3	71
423	The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry, 2001, 49, 39-46.	1.3	158
424	Event-related potentials and genetic risk for schizophrenia. Biological Psychiatry, 2001, 50, 407-417.	1.3	60
425	Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biological Psychiatry, 2001, 50, 98-107.	1.3	289
426	Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry, 2001, 50, 825-844.	1.3	708
427	Anxiety at the Frontier of Molecular Medicine. New England Journal of Medicine, 2001, 344, 1247-1249.	27.0	62
428	Relative Risk of Neurological Signs in Siblings of Patients With Schizophrenia. American Journal of Psychiatry, 2001, 158, 1827-1834.	7.2	95
429	BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. European Journal of Neuroscience, 2001, 14, 135-144.	2.6	179
430	Morphology of the Frontal Operculum: A Volumetric Magnetic Resonance Imaging Study of the Pars Triangularis. Journal of Neuroimaging, 2001, 11, 153-159.	2.0	34
431	Associating Semantic Space Abnormalities With Formal Thought Disorder in Schizophrenia: Use of Triadic Comparisons. Journal of Clinical and Experimental Neuropsychology, 2001, 23, 285-296.	1.3	15
432	Evidence for Abnormal Cortical Functional Connectivity During Working Memory in Schizophrenia. American Journal of Psychiatry, 2001, 158, 1809-1817.	7.2	537

#	Article	IF	CITATIONS
433	Selective Relationship Between PrefrontalN-Acetylaspartate Measures and Negative Symptoms in Schizophrenia. American Journal of Psychiatry, 2000, 157, 1646-1651.	7.2	108
434	Relative Risk of Attention Deficits in Siblings of Patients With Schizophrenia. American Journal of Psychiatry, 2000, 157, 1309-1316.	7.2	161
435	The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Development and Psychopathology, 2000, 12, 501-527.	2.3	453
436	Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone. Journal of Comparative Neurology, 2000, 423, 359-372.	1.6	127
437	Differential DNA damage in response to the neonatal and adult excitotoxic hippocampal lesion in rats. European Journal of Neuroscience, 2000, 12, 4424-4433.	2.6	18
438	To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test. Neuropsychopharmacology, 2000, 23, 223-239.	5.4	567
439	Specific Relationship Between Prefrontal Neuronal <i>N</i> -Acetylaspartate and Activation of the Working Memory Cortical Network in Schizophrenia. American Journal of Psychiatry, 2000, 157, 26-33.	7.2	148
440	Proton MR Spectroscopic Imaging without Water Suppression. Radiology, 2000, 217, 296-300.	7.3	50
441	Thought Disorder in Schizophrenia: A Reappraisal of Older Formulations and an Overview of Some Recent Studies. Cognitive Neuropsychiatry, 2000, 5, 1-19.	1.3	70
442	Cognitive Impairments in Patients With Schizophrenia Displaying Preserved and Compromised Intellect. Archives of General Psychiatry, 2000, 57, 907.	12.3	479
443	A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biological Psychiatry, 2000, 47, 643-649.	1.3	452
444	Neuropharmacological studies with spect in neuropsychiatric disorders. Nuclear Medicine and Biology, 2000, 27, 677-682.	0.6	21
445	Effects of Dextroamphetamine on Cognitive Performance and Cortical Activation. NeuroImage, 2000, 12, 268-275.	4.2	274
446	Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse, 1999, 32, 71-79.	1.2	57
447	Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. European Journal of Radiology, 1999, 30, 95-104.	2.6	38
448	Organization of the human motor system as studied by functional magnetic resonance imaging. European Journal of Radiology, 1999, 30, 105-114.	2.6	60
449	Proton magnetic resonance spectroscopy in schizophrenia. European Journal of Radiology, 1999, 30, 132-141.	2.6	47
450	In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Research - Neuroimaging, 1999, 90, 81-90.	1.8	41

#	Article	IF	CITATIONS
451	Regional cerebral blood flow in down syndrome adults during the Wisconsin card sorting test: exploring cognitive activation in the context of poor performance. Biological Psychiatry, 1999, 45, 1190-1196.	1.3	15
452	Neuropsychological performance of monozygotic twins discordant for bipolar disorder. Biological Psychiatry, 1999, 45, 639-646.	1.3	163
453	The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biological Psychiatry, 1999, 45, 660-667.	1.3	106
454	Neonatal Hippocampal Damage in the Rat: A Heuristic Model of Schizophrenia. Psychiatric Annals, 1999, 29, 157-160.	0.1	5
455	Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature, 1998, 393, 169-171.	27.8	178
456	Changing patterns of brain activation during maze learning. Brain Research, 1998, 793, 29-38.	2.2	42
457	Reproducibility of Proton Magnetic Resonance Spectroscopic Imaging in Patients with Schizophrenia. Neuropsychopharmacology, 1998, 18, 1-9.	5.4	69
458	Functional Magnetic Resonance Imaging Brain Mapping in Psychiatry: Methodological Issues Illustrated in a Study of Working Memory in Schizophrenia. Neuropsychopharmacology, 1998, 18, 186-196.	5.4	293
459	Schizophrenia as a developmental disorder of the cerebral cortex. Current Opinion in Neurobiology, 1998, 8, 157-161.	4.2	143
460	Hemispheric control of motor function: a whole brain echo planar fMRI study. Psychiatry Research - Neuroimaging, 1998, 83, 7-22.	1.8	86
461	In vivo imaging of brain nicotinic acetylcholine receptors with 5-[1231]iodo-A-85380 using single photon emission computed tomography. Life Sciences, 1998, 63, PL355-PL360.	4.3	53
462	Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study. Biological Psychiatry, 1998, 43, 641-648.	1.3	191
463	Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biological Psychiatry, 1998, 44, 941-950.	1.3	131
464	Uncoupling Cognitive Workload and Prefrontal Cortical Physiology: A PET rCBF Study. NeuroImage, 1998, 7, 296-303.	4.2	146
465	Quantitation of Regional Cerebral Blood Flow Increases in Prefrontal Cortex during a Working Memory Task: A Steady-State Arterial Spin-Tagging Study. NeuroImage, 1998, 8, 44-49.	4.2	34
466	MRI Asymmetries of Broca's Area: The Pars Triangularis and Pars Opercularis. Brain and Language, 1998, 64, 282-296.	1.6	235
467	Types and characteristics of remote memory impairment in schizophrenia. Schizophrenia Research, 1998, 30, 155-163.	2.0	85
468	Operant conditioning and the orbitofrontal cortex in schizophrenic patients: unexpected evidence for intact functioning. Schizophrenia Research, 1998, 30, 169-174.	2.0	127

#	Article	IF	CITATIONS
469	Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophrenia Research, 1998, 31, 19-26.	2.0	122
470	Reduced Central Serotonin Transporters in Alcoholism. American Journal of Psychiatry, 1998, 155, 1544-1549.	7.2	263
471	Cognitive Substrates of Thought Disorder, I: The Semantic System. American Journal of Psychiatry, 1998, 155, 1671-1676.	7.2	276
472	Cognitive Substrates of Thought Disorder, II: Specifying a Candidate Cognitive Mechanism. American Journal of Psychiatry, 1998, 155, 1677-1684.	7.2	116
473	Common Pattern of Cortical Pathology in Childhood-Onset and Adult-Onset Schizophrenia as Identified by Proton Magnetic Resonance Spectroscopic Imaging. American Journal of Psychiatry, 1998, 155, 1376-1383.	7.2	114
474	In Vivo Association Between Alcohol Intoxication, Aggression, and Serotonin Transporter Availability in Nonhuman Primates. American Journal of Psychiatry, 1998, 155, 1023-1028.	7.2	174
475	Dopamine, the prefrontal cortex and schizophrenia. Journal of Psychopharmacology, 1997, 11, 123-131.	4.0	254
476	Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. British Journal of Psychiatry, 1997, 171, 574-577.	2.8	53
477	Abnormal functional lateralization of the sensorimotor cortex in patients with schizophrenia. NeuroReport, 1997, 8, 2977-2984.	1.2	85
478	Quantitation of Regional Cerebral Blood Flow Increases during Motor Activation: A Steady-State Arterial Spin Tagging Study. NeuroImage, 1997, 6, 104-112.	4.2	61
479	Neurobiology of schizophrenia. Current Opinion in Neurobiology, 1997, 7, 701-707.	4.2	147
480	Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Research - Neuroimaging, 1997, 75, 91-101.	1.8	86
481	Visuospatial working memory in patients with schizophrenia. Biological Psychiatry, 1997, 41, 43-49.	1.3	143
482	Cortical abnormality in schizophrenia: An in vivo application of the gyrification index. Biological Psychiatry, 1997, 41, 995-999.	1.3	102
483	Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 932-942.	4.3	183
484	Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Developmental Brain Research, 1997, 101, 17-25.	1.7	62
485	Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology, 1997, 132, 303-310.	3.1	320
486	Localized echo-volume imaging methods for functional MRI. Journal of Magnetic Resonance Imaging, 1997, 7, 371-375.	3.4	31

#	Article	IF	CITATIONS
487	Correction for vascular artifacts in cerebral blood flow values measured by using arterial spin tagging techniques. Magnetic Resonance in Medicine, 1997, 37, 226-235.	3.0	289
488	In vivo characterization of extracellular GABA release in the caudate nucleus and prefrontal cortex of the rhesus monkey. , 1997, 25, 285-292.		6
489	Analysis of the metabolites of [I-123]?-CIT in plasma of human and nonhuman primates. , 1997, 25, 306-308.		5
490	Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse, 1997, 27, 168-176.	1.2	97
491	Analysis of Interpolation Effects in the Reslicing of Functional MR Images. Journal of Computer Assisted Tomography, 1997, 21, 803-810.	0.9	47
492	fMRI Applications in Schizophrenia Research. NeuroImage, 1996, 4, S118-S126.	4.2	86
493	Isolating the Mnemonic Component in Spatial Delayed Response: A Controlled PET15O-Labeled Water Regional Cerebral Blood Flow Study in Normal Humans. NeuroImage, 1996, 3, 69-78.	4.2	51
494	Cortical gyral anatomy and gross brain dimensions in monozygotic twins discordant for schizophrenia. Schizophrenia Research, 1996, 22, 27-40.	2.0	68
495	Functional lateralization of the prefrontal cortex during traditional frontal lobe tasks. Biological Psychiatry, 1996, 39, 389-399.	1.3	24
496	Dextroamphetamine Enhances "Neural Network-Specific―Physiological Signals: A Positron-Emission Tomography rCBF Study. Journal of Neuroscience, 1996, 16, 4816-4822.	3.6	147
497	An investigation of semantic space in patients with schizophrenia. Journal of the International Neuropsychological Society, 1996, 2, 267-273.	1.8	83
498	PET validation of a novel prefrontal task: Delayed response alternation Neuropsychology, 1996, 10, 3-10.	1.3	72
499	Verbal fluency deficits in patients with schizophrenia: Semantic fluency is differentially impaired as compared with phonologic fluency Neuropsychology, 1996, 10, 573-577.	1.3	87
500	Cognitive activation during PET: A case study of monozygotic twins discordant for closed head injury. Neuropsychologia, 1996, 34, 689-697.	1.6	15
501	Fast 3D functional magnetic resonance imaging at 1.5 T with spiral acquisition. Magnetic Resonance in Medicine, 1996, 36, 620-626.	3.0	72
502	Reproducibility of human 3D fMRI brain maps acquired during a motor task. , 1996, 4, 113-121.		54
503	Amphetamine-inducedc-fos mRNA expression is altered in rats with neonatal ventral hippocampal damage. , 1996, 23, 292-301.		31
504	Functional Mapping of Human Sensorimotor Cortex with 3D BOLD fMRI Correlates Highly with H215O PET rCBF. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 755-764.	4.3	119

#	Article	IF	CITATIONS
505	Amphetamineâ€induced cfos mRNA expression is altered in rats with neonatal ventral hippocampal damage. Synapse, 1996, 23, 292-301.	1.2	2
506	Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. European Archives of Psychiatry and Clinical Neuroscience, 1995, 245, 224-230.	3.2	9
507	Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse, 1995, 20, 125-130.	1.2	81
508	Normal Asymmetry of the Planum Temporale in Patients with Schizophrenia. British Journal of Psychiatry, 1995, 166, 742-749.	2.8	80
509	BRAIN IMAGING IN SCHIZOPHRENIA. Annual Review of Medicine, 1995, 46, 113-122.	12.2	63
510	Midline abnormalities and psychopathology: how reliable is the midsagittal magnetic resonance "window―into the brain?. Psychiatry Research - Neuroimaging, 1995, 61, 33-42.	1.8	8
511	Cognitive deficits and the neurobiology of schizophrenia. Current Opinion in Neurobiology, 1995, 5, 225-230.	4.2	62
512	Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biological Psychiatry, 1995, 37, 175-182.	1.3	27
513	Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biological Psychiatry, 1995, 38, 255-262.	1.3	50
514	Diurnal variation in tardive dyskinesia. Psychiatry Research, 1995, 56, 53-57.	3.3	20
515	Verbal working memory dysfunction in schizophrenia: use of a Brown-Peterson paradigm. Psychiatry Research, 1995, 56, 155-161.	3.3	102
516	Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophrenia Research, 1995, 17, 77-84.	2.0	170
517	Memory and intelligence in lateralized temporal lobe epilepsy and schizophrenia. Schizophrenia Research, 1995, 17, 59-65.	2.0	29
518	Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophrenia Research, 1995, 16, 87-110.	2.0	475
519	Neuropsychology and neurophysiology of schizophrenia. Current Opinion in Psychiatry, 1995, 8, 34-40.	6.3	10
520	Electroencephalographic Abnormalities in Monozygotic Twins with Tourette's Syndrome. British Journal of Psychiatry, 1994, 164, 811-817.	2.8	20
521	Subchronic Treatment with Haloperidol and Clozapine in Rats with Neonatal Excitotoxic Hippocampal Damage. Neuropsychopharmacology, 1994, 10, 199-205.	5.4	133
522	Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse, 1994, 18, 178-189.	1.2	83

#	Article	IF	CITATIONS
523	3-dimensional functional imaging of human brain using echo-shifted FLASH MRI. Magnetic Resonance in Medicine, 1994, 32, 150-155.	3.0	65
524	Functional brain MR imaging based on bolus tracking with a fast T2â^—-sensitized gradient-echo method. Magnetic Resonance Imaging, 1994, 12, 379-385.	1.8	36
525	An improved methodology for routine in vivo microdialysis in non-human primates. Journal of Neuroscience Methods, 1994, 55, 1-6.	2.5	23
526	The effects of combined prefrontal cortical and hippocampal damage on dopamine-related behaviors in rats. Pharmacology Biochemistry and Behavior, 1994, 48, 1053-1057.	2.9	27
527	Serum antibody for somatostatin-14 and prodynorphin 209–240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biological Psychiatry, 1994, 35, 335-344.	1.3	43
528	Gonadectomy does not prevent novelty or drug-induced motor hyperresponsiveness in rats with neonatal hippocampal damage. Developmental Brain Research, 1994, 78, 253-258.	1.7	41
529	Cerebral ventricular enlargement in schizophreniform disorder does not progress A seven year follow-up study. Schizophrenia Research, 1994, 14, 23-28.	2.0	90
530	CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophrenia Research, 1994, 12, 35-41.	2.0	51
531	Autoradiographic characterization of 1251-neurotensin binding sites in human entorhinal cortex. Brain Research Bulletin, 1994, 35, 353-358.	3.0	7
532	Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia. Psychiatry Research - Neuroimaging, 1994, 55, 51-61.	1.8	122
533	Schizophrenia, training paradigms, and the Wisconsin Card Sorting Test redux. Schizophrenia Research, 1994, 11, 291-296.	2.0	52
534	Is There Cognitive Decline in Schizophrenia?. British Journal of Psychiatry, 1994, 164, 494-500.	2.8	135
535	Synthesis of a novel 123I-labelled derivative of GBR12783, a potential agent for SPECT imaging of dopamine-reuptake sites. Journal of Labelled Compounds and Radiopharmaceuticals, 1993, 33, 493-500.	1.0	3
536	Pharmacological and Regional Characterization of [3H]LY278584 Binding Sites in Human Brain. Journal of Neurochemistry, 1993, 60, 730-737.	3.9	55
537	Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala. Brain Research, 1993, 616, 53-57.	2.2	28
538	Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxic Hippocampal Damage: A Potential Animal Model of Schizophrenia. Neuropsychopharmacology, 1993, 9, 67-75.	5.4	669
539	Synthesis and binding characteristics of potential SPECT imaging agents for .sigma1 and .sigma2 binding sites. Journal of Medicinal Chemistry, 1993, 36, 566-571.	6.4	20
540	Regional cerebral blood flow during the wisconsin card sorting test in normal subjects studied by xenon-133 dynamic SPECT: Comparison of absolute values, percent distribution values and covariance analysis. Psychiatry Research - Neuroimaging, 1993, 50, 177-192.	1.8	70

#	Article	IF	CITATIONS
541	Procedure for volumetric analysis of brain MRI images by segmentation into CSF spaces, cortical gray, cortical white, and subcortical gray matter using a semi-automated multi-level threshold technique. Schizophrenia Research, 1993, 9, 206.	2.0	2
542	A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. Psychiatry Research, 1993, 49, 41-62.	3.3	48
543	Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Developmental Brain Research, 1993, 75, 213-222.	1.7	181
544	Sylvian fissure asymmetries in monozygotic twins: A test of laterality in schizophrenia. Biological Psychiatry, 1993, 34, 853-863.	1.3	66
545	Learning and memory in monozygotic twins discordant for schizophrenia. Psychological Medicine, 1993, 23, 71-85.	4.5	194
546	The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia. British Journal of Psychiatry, 1993, 162, 43-48.	2.8	283
547	Three-Dimensional Surface Rendering in MRI Morphometry. Journal of Computer Assisted Tomography, 1993, 17, 529-535.	0.9	55
548	Age-Related Prognostic Factors in the Severity of Illness of Tourette's Syndrome in Monozygotic Twins. Journal of Neuropsychiatry and Clinical Neurosciences, 1993, 5, 178-182.	1.8	0
549	Is the Mechanism of Prefrontal Hypofunction in Depression the Same as in Schizophrenia?. British Journal of Psychiatry, 1993, 162, 183-192.	2.8	119
550	Dichotic listening in monozygotic twins discordant and concordant for schizophrenia. Schizophrenia Research, 1992, 7, 177-183.	2.0	21
551	Visual orienting in schizophrenia. Schizophrenia Research, 1992, 7, 203-209.	2.0	41
552	Somatostatin-like immunoreactivity in CSF of schizophrenic patients during haloperidol treatment. Biological Psychiatry, 1992, 31, 962-964.	1.3	2
553	Laterality of appendicular tardive dyskinesia in chronic schizophrenia. Biological Psychiatry, 1992, 31, 1098-1109.	1.3	3
554	Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Research, 1992, 585, 1-6.	2.2	208
555	Neuroimaging in neuropsychiatry. New Directions for Mental Health Services, 1992, 1992, 77-82.	0.4	4
556	Dopamine and schizophrenia—a cortically corrective perspective. Seminars in Neuroscience, 1992, 4, 179-188.	2.2	52
557	Ibotenic acid lesions of medial prefrontal cortex augment swim-stress-induced locomotion. Pharmacology Biochemistry and Behavior, 1992, 41, 607-609.	2.9	37
558	Serotonin depletion causes long-term reduction of exploration in the rat. Pharmacology Biochemistry and Behavior, 1992, 43, 1247-1252.	2.9	49

#	Article	IF	CITATIONS
559	18. Evidence against progression of in vivo anatomical abnormalities in schizophrenia. Schizophrenia Research, 1991, 5, 210.	2.0	11
560	Characterization of [1251]SCH 23982 binding in human brain: Comparison with [3H]SCH 23390. Neuroscience Letters, 1991, 131, 273-276.	2.1	14
561	Lack of a bimodal distribution of ventricular size in schizophrenia: A Gaussian mixture analysis of 1056 cases and controls. Biological Psychiatry, 1991, 30, 887-903.	1.3	112
562	Microinjection of apomorphine into the prefrontal cortex of the rat reduces dopamine metabolite concentrations in microdialysate from the caudate nucleus. Biological Psychiatry, 1991, 29, 703-706.	1.3	56
563	Computed tomography measurements of brain density in schizophrenia. Biological Psychiatry, 1991, 29, 745-756.	1.3	3
564	Hippocampal injury and chronic schizophrenia. Biological Psychiatry, 1991, 29, 509-510.	1.3	13
565	Dorsal hippocampal lesion abolishes the response to FG-7142 in the rat. Pharmacology Biochemistry and Behavior, 1991, 40, 169-172.	2.9	10
566	Dorsal hippocampal lesion does not affect dopaminergic indices in the basal ganglia. Pharmacology Biochemistry and Behavior, 1991, 40, 181-184.	2.9	20
567	EEG laterality in the era of structural brain imaging. Brain Topography, 1991, 3, 381-390.	1.8	23
568	The Distribution of Cerebral Muscarinic Acetylcholine Receptors In Vivo in Patients With Dementia. Archives of Neurology, 1991, 48, 169.	4.5	126
569	Schizophrenia and the normal functional development of the prefrontal cortex. Development and Psychopathology, 1990, 2, 409-424.	2.3	12
570	Ibotenic acid lesions of the medial prefrontal cortex potentiate FG-7142-induced attenuation of exploratory activity in the rat. Pharmacology Biochemistry and Behavior, 1990, 36, 695-697.	2.9	38
571	Anatomical Abnormalities in the Brains of Monozygotic Twins Discordant for Schizophrenia. New England Journal of Medicine, 1990, 322, 789-794.	27.0	990
572	The Brain in Schizophrenia. Seminars in Neurology, 1990, 10, 276-286.	1.4	23
573	Effect of ibotenic acid lesions of the medial prefrontal cortex on amphetamine-induced locomotion and regional brain catecholamine concentrations in the rat. Brain Research, 1990, 534, 263-272.	2.2	124
574	The relationship of occipital skull asymmetry to brain parenchymal measures in schizophrenia. Schizophrenia Research, 1989, 2, 465-472.	2.0	14
575	Shape analysis of the middle cranial fossa of schizophrenic patients. Schizophrenia Research, 1989, 2, 333-338.	2.0	14
576	Increased temporal lobe glucose use in chronic schizophrenic patients. Biological Psychiatry, 1989, 25, 835-851.	1.3	131

#	Article	IF	CITATIONS
577	Characterization of dopamine uptake sites in the human and rat frontal cortex. Biological Psychiatry, 1989, 25, A51.	1.3	0
578	Recall memory deficit in schizophrenia. Schizophrenia Research, 1989, 2, 251-257.	2.0	189
579	Intellectual impairment in adolescent psychosis. Schizophrenia Research, 1988, 1, 261-266.	2.0	40
580	Personality variables, neurological and psychopathological symptoms in patients suffering from spasmodic torticollis. Comprehensive Psychiatry, 1988, 29, 182-187.	3.1	12
581	Mesocortical Dopaminergic Function and Human Cognition. Annals of the New York Academy of Sciences, 1988, 537, 330-338.	3.8	85
582	Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Research, 1988, 25, 233-242.	3.3	29
583	Probing Prefrontal Function in Schizophrenia With Neuropsychological Paradigms. Schizophrenia Bulletin, 1988, 14, 179-183.	4.3	164
584	Dementia Praecox Revisited. British Journal of Psychiatry, 1988, 153, 187-190.	2.8	24
585	The prefrontal cortex — accumbens circuit: Who's in charge?. Behavioral and Brain Sciences, 1987, 10, 217-218.	0.7	6
586	Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Research, 1987, 20, 337-345.	3.3	78
587	Morphological brain abnormalities in schizophrenia determined by computed tomography: A problem of measurement?. Psychiatry Research, 1987, 22, 91-98.	3.3	28
588	Skull Asymmetry and Handedness in Adults: A Possibility of Their Association with Lateral Head Turning in Infancy. Perceptual and Motor Skills, 1987, 65, 415-421.	1.3	11
589	Implications of Normal Brain Development for the Pathogenesis of Schizophrenia. Archives of General Psychiatry, 1987, 44, 660.	12.3	3,463
590	Buspirone, Parkinson's Disease, and the Locus Ceruleus. Clinical Neuropharmacology, 1986, 9, 373-378.	0.7	58
591	Abnormal cerebrospinal fluid protein indices in schizophrenia. Biological Psychiatry, 1985, 20, 1039-1046.	1.3	67
592	Computed tomography (CT) findings in schizophrenia: Speculation on the meaning of it all. Journal of Psychiatric Research, 1984, 18, 477-490.	3.1	85
593	Enlarged Cerebral Ventricles in Schizophrenia. Psychiatric Annals, 1983, 13, 412-418.	0.1	11
594	Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects. Psychiatry Research, 1982, 7, 1-7.	3.3	19

#	Article	IF	CITATIONS
595	Haloperidol-Induced Changes in Blink Rates Correlate with Changes in BPRS Score. British Journal of Psychiatry, 1982, 140, 503-507.	2.8	31
596	Asymmetrical volumes of the right and left frontal and occipital regions of the human brain. Annals of Neurology, 1982, 11, 97-100.	5.3	156
597	Familial aspects of CT scan abnormalities in chronic schizophrenic patients. Psychiatry Research, 1981, 4, 65-71.	3.3	159
598	HLA-A2 Antigen in Schizophrenic Patients with Reversed Cerebral Asymmetry. British Journal of Psychiatry, 1981, 138, 240-243.	2.8	27
599	Drug Withdrawal in Chronic Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1981, 1, 120-123.	1.4	19
600	Quantitative Determination of Immunoglobulins in CSF and Plasma of Chronic Schizophrenic Patients. British Journal of Psychiatry, 1981, 139, 513-518.	2.8	51
601	HLA Antigens in Schizophrenia: Differences between Patients with and without Evidence of Brain Atrophy. British Journal of Psychiatry, 1980, 136, 243-248.	2.8	39
602	Cognitive Impairment Associated with Morphological Brain Abnormalities on Computed Tomography in Chronic Schizophrenic Patients. Journal of Nervous and Mental Disease, 1980, 168, 305-308.	1.0	119
603	Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology, 1980, 71, 291-297.	3.1	58
604	Computed Tomography in Tardive Dyskinesia. British Journal of Psychiatry, 1980, 136, 606-607.	2.8	13
605	Effect of a cocktail on diazepam absorption. Psychopharmacology, 1978, 57, 199-203.	3.1	35
606	Problems with Drug Interactions in Treating Brain Disorders. Psychiatric Clinics of North America, 1978, 1, 51-69.	1.3	7
607	Strategies for cellular deconvolution in human brain RNA sequencing data. F1000Research, 0, 10, 750.	1.6	4